Possibilities of Computed Tomography of the Heart in Risk Stratification and Determination of Optimal Strategy of Primary Prevention of Cardiovascular Complications of Atherosclerosis
https://doi.org/10.18087/cardio.2019.6.n685
Abstract
Modern strategies of primary prevention of cardiovascular complications of atherosclerotic etiology are presented in this article: traditional approach based on assessment of risk of development of complication and coming to replace it concept of prevention based on direct application of results of prospective clinical studies. The article contains detailed presentation of new opportunities of computer tomography of the heart allowing to substantially elevate precision of assessment of risk of cardiovascular complications of atherosclerotic etiology. Main attention is paid to the coronary artery calcification index, which determination substantially simpli- fies decision making relative to strategy of primary prevention in clinical practice
About the Authors
Ya. I. Ashikhmin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Ashikhmin Yaroslav I. – MD, PhD, cardiologist
Moscow
V. E. Sinitsyn
Moscow State University
Moscow
Moscow
N. V. Plieva
Sechenov First Moscow State Medical University (Sechenov University)
Moscow
Moscow
D. Yu. Shchekochikhin
Sechenov First Moscow State Medical University (Sechenov University)
Moscow
Moscow
F. Yu. Kopylov
Sechenov First Moscow State Medical University (Sechenov University)
Moscow
Moscow
References
1. Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s heart disease: a textbook of cardiovascular medicine. 2-Volume Set. Tenth edition. -Philadelphia, PA: Elsevier/Saunders, 2015. - 2040p. ISBN 978-1-4557-5134-1
2. Kopylov Ph.Yu., Bykova А.A., Shchekochikhin D.Yu., Elmanaa Kh.E., Dzyundzya A. N., Vasilevsky Yu. V. et al. Asymptomatic atherosclerosis of the brachiocephalic arteries – modern approaches to diagnosis and treatment. Therapeutic Archive. 2017;89(4):95–100. [Russsian]
3. Belenkov Yu. N. Cardiology in our country. What will it be tomorrow. Creative cardiology. 2007;1–2:11–9. [Russian]
4. Ternovaya E. S., Volel B. A., Troshina D. V., Zakharov V. V., Kopylov Ph. Yu. Personalized approach to treatment and rehabilitation in patients with cardiovascular diseases (on the model of arterial hypertension and chronic heart failure). Russian Journal of Cardiology. 2017;22(7):152–61. [Russian]. DOI: 10.15829/1560-4071-2017-7-152-161
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97. PMID: 11368702
6. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2016;37(29):2315–81. DOI: 10.1093/eurheartj/ehw106
7. Loprinzi PD. Objectively-measured physical activity and predicted 10-yr risk for a first atherosclerotic cardiovascular disease (ASCVD) event using the pooled cohort risk equations among US adults. International Journal of Cardiology. 2015;199:31–2. DOI: 10.1016/j.ijcard.2015.06.161
8. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999– 3058. DOI: 10.1093/eurheartj/ehw272
9. Boytsov S. A., Pogosova N. V., Bubnova M. G., Drapkina O. M., Gavrilova N. E., Yeganyan R. A. et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23(6):7–122. [Russian]. DOI: 10.15829/1560-4071-2018-6-7-122
10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hyper- tension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 2013;34(28):2159–219. DOI: 10.1093/eurheartj/eht151
11. Chazova I. E., Ratova L. G., Boytsov S. A., Nebieridze D. V., Karpov Yu. A., Belousov Yu. B. et al. Diagnosis and treatment of arterialhypertension(Recommendationsofthe Russian Medical Society on Arterial Hypertension and the All-Russian Scientific Society of Cardiology). Systemic Hypertensions. 2010;3:5–26. [Russian]
12. Ezhov M. V., Sergienko I. V., Aronov D. M., Arabidze G. G., Akhmedzhanov N. M., Bazhan S. S. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision. Atherosclerosis and Dyslipidemias. 2017;3:5–22. [Russian]
13. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035–87. DOI: 10.1093/eurheartj/eht108
14. Gadekar T, Cariappa MP. Overweight and obesity management guidelines 2016. Medical Journal Armed Forces India. 2017;73(1):100. DOI: 10.1016/j.mjafi.2016.11.014
15. Nedogoda S. V., Barykina I. N., Salasyuk A. S. National clinical guidelines for obesity: concept and perspectives. Journal of Volgograd State Medical University. 2017;1(61):134–40. [Russian]
16. Drapkina O. M., Ashikhmin Ya. I. Subclinical atherosclerosis: “portrait” of the disease, diagnosis and prevention of cardiovascular complications. Russian Heart Journal. 2011;10(6):369–76. [Russian]
17. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta- analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670–81. DOI: 10.1016/S0140-6736(10)61350-5
18. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195–207. DOI: 10.1056/ NEJMoa0807646
19. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 2016;374(21):2021– 31. DOI: 10.1056/NEJMoa1600176
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22. PMID: 9613910
21. Hawa MI, Buchan AP, Ola T, Wun CC, DeMicco DA, Bao W et al. LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes. Diabetes Care. 2014;37(6):1643–9. DOI: 10.2337/dc13-2383
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. New England Journal of Medicine. 1995;333(20):1301–8. DOI: 10.1056/NEJM199511163332001
23. Bibbins-Domingo K, on behalf of the U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2016;164(12):836–45. DOI: 10.7326/M16-0577
24. Sinitsyn V. E., Fomina I. G., Pisarev M. V., Gagarina N. V. Diagnostic and prognostic significance of detecting coronary calcification in the preclinical stage of coronary heart disease. Cardiovascular Therapy and Prevention. 2004;3(5):118–25. [Russian]
25. Haberl R, Becker A, Leber A, Knez A, Becker C, Lang C et al. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. Journal of the American College of Cardiology. 2001;37(2):451–7. PMID: 11216962
26. Sinitsyn V. E., Voronov D. A., Morozov S. P. The degree of coronary artery calcification as a prognostic factor for complications of cardiovascular diseases without clinical manifestations: the results of meta-analysis. Therapeutic Archive. 2006;78(9):22–7. [Russian]
27. Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ et al. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Journal of the American College of Cardiology. 2015;66(15):1657–68. DOI: 10.1016/j.jacc.2015.07.066
28. Tota-Maharaj R, Blaha MJ, McEvoy JW, Blumenthal RS, Muse ED, Budoff MJ et al. Coronary artery calcium for the prediction of mortality in young adults 75 years old. European Heart Journal. 2012;33(23):2955–62. DOI: 10.1093/eurheartj/ehs230
29. Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2018;11(2):221–30. DOI: 10.1016/j.jcmg.2017.01.029
30. Michos ED, Blaha MJ, Blumenthal RS. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. Mayo Clinic Proceedings. 2017;92(12):1831–41. DOI: 10.1016/j.mayocp.2017.10.001
31. Belkind M. В., Sinitsyn V. E., Lyakishev A. A., Naumov V. G., Ternovoi S. K. Coronary calcium and statin treatment. Therapeutic Archive. 2006;78(4):53–6. [Russian]
32. Boytsov S. A., Karpov Yu. A., Kukharchuk V. V., Rogoza A. N., Balakhonova T. V., Urazalina S. J. et al. Identification of Patients at High Cardiovascular Risk: Problems and Possible Solution. Atherosclerosis and Dyslipidemias. 2010;1(1):8–14. [Russian]
33. Shlyakhto E. V., Arutyunov G. P., Belenkov Yu. N. National guidelines for determining risk and preventing sudden cardiac death (shortened version). The Russian Archives of Internal Medicine. 2013;4:5–15. [Russian]
34. MESA. MESA Risk Score Calculator. Av. at: https://www.mesanhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx.
35. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR et al. Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups. New England Journal of Medicine. 2008;358(13):1336–45. DOI: 10.1056/NEJMoa072100
36. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E et al. Diagnostic Performance of 64-Multidetector Row Coronary Computed Tomographic Angiography for Evaluation of Coronary Artery Stenosis in Individuals Without Known Coronary Artery Disease. Journal of the American College of Cardiology. 2008;52(21):1724–32. DOI: 10.1016/j.jacc.2008.07.031
37. Weir-McCall JR, Blanke P, Sellers SL, Ahmadi AA, Andreini D, Budoff MJ et al. Impact of Non-obstructive left main disease on the progression of coronary artery disease: A PARADIGM substudy. Journal of Cardiovascular Computed Tomography. 2018;12(3):231–7. DOI: 10.1016/j.jcct.2018.05.011
38. Song F-X, Zhou J, Zhou J-J, Shi Y-X, Zeng M-S, Zhang Z-Y et al. The diagnosis of coronary plaque stability by multi-slice computed tomography coronary angiography. Journal of Thoracic Disease. 2018;10(4):2365–76. DOI: 10.21037/jtd.2018.04.43
39. Hell MM, Motwani M, Otaki Y, Cadet S, Gransar H, Miranda- Peats R et al. Quantitative global plaque characteristics from coronary computed tomography angiography for the prediction of future cardiac mortality during long-term follow-up. European Heart Journal - Cardiovascular Imaging. 2017;18(12):1331–9. DOI: 10.1093/ehjci/jex183
40. Quillard T, Franck G, Mawson T, Folco E, Libby P. Mechanisms oferosionofatheroscleroticplaques: Current Opinionin Lipidology. 2017;28(5):434–41. DOI: 10.1097/MOL.0000000000000440
Review
For citations:
Ashikhmin Ya.I., Sinitsyn V.E., Plieva N.V., Shchekochikhin D.Yu., Kopylov F.Yu. Possibilities of Computed Tomography of the Heart in Risk Stratification and Determination of Optimal Strategy of Primary Prevention of Cardiovascular Complications of Atherosclerosis. Kardiologiia. 2019;59(6):70-80. (In Russ.) https://doi.org/10.18087/cardio.2019.6.n685
Views:
2146
Email this article 
Post a Comment 
